QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Outlook Therapeutics (OTLK) Stock Forecast & Price Target

$0.48
+0.01 (+2.11%)
(As of 11/28/2023 ET)
Compare
Today's Range
$0.47
▼
$0.50
50-Day Range
$0.21
▼
$0.66
52-Week Range
$0.20
▼
$2.03
Volume
1.38 million shs
Average Volume
3.90 million shs
Market Capitalization
$126.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.60
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Outlook Therapeutics Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$4.60
849.82% Upside
High Forecast$10.00
Average Forecast$4.60
Low Forecast$1.00
TypeCurrent Forecast
11/28/22 to 11/28/23		1 Month Ago
10/29/22 to 10/29/23		3 Months Ago
8/30/22 to 8/30/23		1 Year Ago
11/28/21 to 11/28/22
Consensus Rating
Hold
Hold
Hold
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
Hold
6 Hold rating(s)
7 Hold rating(s)
5 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.60$4.83$5.50$6.67
Predicted Upside849.82% Upside487.12% Upside360.09% Upside431.63% Upside
Get Outlook Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.


OTLK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OTLK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Outlook Therapeutics Stock vs. The Competition

TypeOutlook TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.14
2.67
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside849.82% Upside1,024.62% Upside2,838.32% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/3/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeNeutral ➝ Buy$1.00 ➝ $2.00+488.22%
8/31/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Gataulin
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Neutral
8/30/2023Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating		K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Hold
8/30/2023Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Z. Jallah
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOverweight ➝ Equal Weight
8/30/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
8/30/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		K. Kluska
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOverweight ➝ Neutral$4.50 ➝ $1.00+340.71%
8/30/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
(Data available from 11/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












OTLK Price Target - Frequently Asked Questions

What is Outlook Therapeutics's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Outlook Therapeutics stock is Hold based on the current 6 hold ratings and 1 buy rating for OTLK. The average twelve-month price prediction for Outlook Therapeutics is $4.60 with a high price target of $10.00 and a low price target of $1.00. Learn more on OTLK's analyst rating history.

Do Wall Street analysts like Outlook Therapeutics more than its competitors?

Analysts like Outlook Therapeutics less than other Medical companies. The consensus rating for Outlook Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how OTLK compares to other companies.

Is Outlook Therapeutics being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Outlook Therapeutics's stock had 7 downgrades and 1 upgrade by analysts.

Does Outlook Therapeutics's stock price have much upside?

According to analysts, Outlook Therapeutics's stock has a predicted upside of 481.88% based on their 12-month stock forecasts.

What analysts cover Outlook Therapeutics?

Outlook Therapeutics has been rated by Brookline Capital Management, BTIG Research, Cantor Fitzgerald, Capital One Financial, Chardan Capital, Guggenheim, and HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:OTLK) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -